167 research outputs found

    Overexpressed vs mutated Kras in murine fibroblasts: a molecular phenotyping study

    Get PDF
    Ras acts in signalling pathways regulating the activity of multiple cellular functions including cell proliferation, differentiation, and apoptosis. Amino-acid exchanges at position 12, 13, or 61 of the Kras gene convert the proto-oncogene into an activated oncogene. Until now, a direct comparison of genome-wide expression profiling studies of Kras overexpression and different Kras mutant forms in a single assay system has not been carried out. In our study, we focused on the direct comparison of global gene expression effects caused by mutations in codon 12 or 13 of the Kras gene and Kras overexpression in murine fibroblasts. We determined Kras cellular mRNA, Ras protein and activated Ras protein levels. Further, we compared our data to the proteome analysis of the same transfected cell lines. Both overexpression and mutations of Kras lead to common altered gene expression patterns. Only two genes, Lox and Col1a1, were reversely regulated in the Kras transfectants. They may contribute to the higher aggressiveness of the Kras codon 12 mutation in tumour progression. The functional annotation of differentially expressed genes revealed a high frequency of proteins involved in tumour growth and angiogenesis. These data further support the important role of these genes in tumour-associated angiogenesis

    FTS and 2-DG induce pancreatic cancer cell death and tumor shrinkage in mice

    Get PDF
    The Ras inhibitor S-trans-trans farnesylthiosalicylic acid (FTS) inhibits active Ras, which controls cell proliferation, differentiation, survival, and metabolism. FTS also inhibits HIF1α expression in cancer cells, leading to an energy crisis. The synthetic glucose analog 2-deoxy-D-glucose (2-DG), which inhibits glycolysis, is selectively directed to tumor cells that exhibit increased glucose consumption. The 2-DG enters tumor cells, where it competes with glucose for glycolytic enzymes. In cancer models, as well as in human phase 1 trials, 2-DG inhibits tumor growth without toxicity. We postulated that under normoxic conditions, tumor cells treated with FTS would be more sensitive than normal cells to 2-DG. We show here that combined treatment with FTS and 2-DG inhibited cancer cell proliferation additively, yet induced apoptotic cell death synergistically both in vitro and in vivo. The induced apoptosis was inferred from QVD-OPH inhibition, an increase in cleaved caspase 3, and loss of survivin. FTS and 2-DG when combined, but not separately, also induced an increase in fibrosis of the tumor tissue, chronic inflammation, and tumor shrinkage. Overall, these results suggest a possible new treatment of pancreatic tumors by the combined administration of FTS and 2-DG, which together induce pancreatic tumor cell death and tumor shrinkage under non-toxic conditions

    Nature

    No full text

    Interactions between Ras proteins and their effectors

    No full text

    Cloning and sequencing of the adenylate kinase gene ( adk

    No full text

    Biochemical properties of Ha-Ras encoded P21 mutants

    No full text
    Mutations of the ras proto-oncogenes rasH, rasK and rasN have been found in many human tumours and in the ras genes of the acutely transforming animal retroviruses HaMuSV and KiMuSV. (for reviews see Gibbs et al., 1985; Barbacid, 1987). These mutations were found to be single or double point mutations and could be localized in all cases to two different regions of the amino acid sequence of the ras encoded p21 proteins. Thus, either amino acids 12/13 or amino acids 59/61 were found to be mutated. The retroviral p21 proteins of the Kirsten and Harvey strain of MuSV contain a double mutation involving glycine12 and alanines59, where alanine59 is changed to threonine in both cases (Dhar et al., 1982; Tsuchida et al., 1982; Yasuda et al., 1984)
    • …
    corecore